1801 — Innovent Biologics Share Price
0.000.00%
Last trade - 00:00- HK$60.61bn
- HK$52.65bn
- CNY6.21bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.47 | ||
| Price to Tang. Book | 4.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.48% | ||
| Return on Equity | -8.84% | ||
| Operating Margin | -16.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 1,047.53 | 3,843.82 | 4,269.73 | 4,556.38 | 6,206.07 | 7,386.04 | 9,688.77 | 265.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Innovent Biologics Inc is an investment holding company principally engaged in biopharmaceuticals. The Company and its subsidiaries are engaged in research and development of antibody and protein medicine products, sale and distribution of pharmaceutical products, and provision of consultation and research and development services. The Company's main product is Tyvyt (sintilimab injection), which is used to treat relapsed or refractory classical Hodgkin’s lymphoma. The Company's products also include adalimumab biosimilar IBI-303, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Bevacizumab biosimilar IBI-305 is used to treat metastatic colorectal cancer and advanced, metastatic or recurrent non-small-cell lung cancer (NSCLC). Rituximab biosimilar IBI-301 is used to treat non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Its products are used in oncology, metabolic, immunology and ophthalmology diseases.
Directors
- De-Chao Yu CHM (57)
- Yong Jun Liu PRE
- Hao Xi Ede CFO (62)
- Lok Yee Chan SEC (31)
- Yanju Wang SEC (32)
- Shuyun Chen NED (47)
- Kaixian Chen NID (75)
- Charles Cooney NID (76)
- I-Yin Hsu NID (46)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 28th, 2011
- Public Since
- October 31st, 2018
- No. of Employees
- 4,872
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,622,682,897
- Address
- 168, SUZHOU, 215123
- Web
- https://www.innoventbio.com/
- Phone
- Auditors
- Deloitte Touche Tohmatsu CPA
Upcoming Events for 1801
Half Year 2024 Innovent Biologics Inc Earnings Release
Similar to 1801
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Innovent Biologics share price?
As of Today at 19:11 UTC, shares in Innovent Biologics are trading at HK$37.35. This share price information is delayed by 15 minutes.
How has the Innovent Biologics share price performed this year?
Shares in Innovent Biologics last closed at HK$37.35 and the price had moved by -11.07% over the past 365 days. In terms of relative price strength the Innovent Biologics share price has underperformed the FTSE Developed Asia Pacific Index by -10.46% over the past year.
What are the analyst and broker recommendations for Innovent Biologics?
The overall consensus recommendation for Innovent Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Innovent Biologics dividend yield?
Innovent Biologics does not currently pay a dividend.
Does Innovent Biologics pay a dividend?
Innovent Biologics does not currently pay a dividend.
When does Innovent Biologics next pay dividends?
Innovent Biologics does not currently pay a dividend.
How do I buy Innovent Biologics shares?
To buy shares in Innovent Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Innovent Biologics?
As of the previous close price of HK$37.35, shares in Innovent Biologics had a market capitalisation of HK$60.61bn.
Where are Innovent Biologics shares listed?
Here are the trading details for Innovent Biologics:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1801
What kind of share is Innovent Biologics?
Based on an overall assessment of its quality, value and momentum Innovent Biologics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Innovent Biologics share price forecast for 2024?
The analyst consensus target price for shares in Innovent Biologics is HK$55.40. That is 48.33% above the last closing price of HK$37.35.
Analysts covering Innovent Biologics currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.53 for the next financial year.
What is the trend in the Innovent Biologics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Innovent Biologics. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -23.89%.
As of the last closing price of HK$37.35, shares in Innovent Biologics were trading -1.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Innovent Biologics PE Ratio?
The Innovent Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$37.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Innovent Biologics?
Innovent Biologics' management team is headed by:
- De-Chao Yu - CHM
- Yong Jun Liu - PRE
- Hao Xi Ede - CFO
- Lok Yee Chan - SEC
- Yanju Wang - SEC
- Shuyun Chen - NED
- Kaixian Chen - NID
- Charles Cooney - NID
- I-Yin Hsu - NID